Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update Nov 15, 2017
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc Nov 2, 2017
Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update Aug 15, 2017
Xenetic Biosciences Announces Adjournment of Annual Meeting of Stockholders until Wednesday, August 16, 2017 Jul 18, 2017
Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy for the Treatment of Endometrial Cancer Jun 26, 2017
Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A May 22, 2017
